Agenus Inc.
AGENAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 11, 2026 | H.C. Wainwright | $25.00(+257%) | $7.00 | TheFly | |
| Nov 29, 2024 | H.C. Wainwright | Emily Bodnar | $7.00(+96%) | $3.57 | StreetInsider |
| Jul 19, 2024 | Jefferies | Biren Amin | $7.00(+17%) | $5.99 | StreetInsider |
| Jul 19, 2024 | Robert W. Baird | Colleen Kusy | $8.00(+10%) | $7.30 | TheFly |
| Jul 18, 2024 | H.C. Wainwright | Emily Bodnar | $9.00(+13%) | $7.98 | TheFly |
| Jul 1, 2024 | H.C. Wainwright | Emily Bodnar | $40.00(+377%) | $8.38 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Chardan Capital | maintain | Buy | Oct 26, 2026 |
| Chardan Capital | maintain | Buy | Oct 22, 2026 |
| Chardan Capital | maintain | Buy | Oct 5, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 11, 2026 |
| B. Riley Securities | maintain | Buy | Jul 30, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jul 13, 2026 |
| HC Wainwright & Co. | maintain | Buy | Sep 10, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 28, 2025 |
| HC Wainwright & Co. | upgrade | Neutral →Buy | Jun 4, 2025 |
| H.C. Wainwright | upgrade | Neutral →Buy | Jun 4, 2025 |
| Baird | maintain | Neutral | Jun 4, 2025 |
| HC Wainwright & Co. | maintain | Neutral | May 13, 2025 |
| Baird | maintain | Neutral | May 13, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Apr 30, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Mar 18, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Mar 12, 2025 |
| Baird | maintain | Neutral | Mar 12, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Jan 22, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Dec 5, 2024 |
| HC Wainwright & Co. | maintain | Neutral | Nov 29, 2024 |
| HC Wainwright & Co. | maintain | Neutral | Nov 12, 2024 |
| B. Riley Securities | maintain | Buy | Aug 14, 2024 |
| Jefferies | downgrade | Buy →Hold | Jul 19, 2024 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Jul 18, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 28, 2024 |
Earnings History
Next report: Mar 15, 2027 · EPS est. $-0.30| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $0.02 | $-0.28 | $31.5M | $28.2M |
| Aug 6, 2026 | $-0.01 | $0.04 | $34.5M | $34.0M |
| May 11, 2026 | $1.02 | $2.10 | $33.7M | $129.5M |
| Mar 16, 2026 | $0.56 | $-1.27 | $34.2M | $28.1M |
| Nov 10, 2025 | $1.94 | $2.63 | $30.2M | $28.1M |
| Aug 11, 2025 | $-1.00 | $-0.78 | $25.7M | $25.0M |
| May 12, 2025 | $-1.03 | $-1.61 | $24.1M | $22.1M |
| Mar 11, 2025 | $-2.04 | $-2.36 | $26.8M | $30.1M |
News
Agenus Inc. ( AGEN ) Discusses BOT BAL Development and Planned Phase 3 ROBBIN Trial November 5, 2026 11:30 AM EST Company Participants Zack Armen - Vice President of Investor Relations & Corporate Development Robin Taylor - Chief Commercial Officer Conference Call Participants Michael King - Rodman & Renshaw Research Presentation Michael King Rodman & Renshaw Research All right. It looks like we've got the whole crowd here, so we're going to kick this off.
AGEN's Q3 earnings meet estimates, but a revenue miss weighs on shares as pipeline progress, Armenian drug approvals and new funding emerge as key developments.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new findings from a long-term survivor analysis of its Phase 1b C-800-01 trial evaluating botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, in heavily pretreated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases.…
Agenus NASDAQ: AGEN expects to begin enrolling patients in the next few months for a Phase 3 trial of its investigational immunotherapy combination BOT/BAL in early-stage colon cancer, executives said during an investor event.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Armenia--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the third quarter ended September 30, 2026, and highlighted progress preparing its global randomized Phase 3 ROBBIN trial of botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, plus balstilimab (BAL), an anti-PD-1 antibody, before surgery in patients with high-risk Stage II and Stage III microsatellite-stable (MSS) col…
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #IO--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Chief Commercial Officer, and Zack Armen, Vice President of Corporate Development and Investor Relations, will participate in a virtual fireside chat hosted by Rodman & Renshaw on Thursday, November 5, 2026. The discussion will be moderated by Michael G. King, Jr., Senior Biotechnology Analyst and will focus on the development of botensilimab (BO…
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of results from the investigator-sponsored, multicenter Phase 2 UNICORN trial evaluating short-course preoperative, or neoadjuvant, botensilimab (BOT), Agenus' multifunctional, Fc-enhanced anti-CTLA-4 antibody, alone or in combination with balstilimab (BAL), Agenus' anti-PD-1 antibody, in patients with resectable, locally advanced co…
[url="]Agenus Inc. (Nasdaq: AGEN)[/url], a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch repair-deficient (dMMR)
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch repair-deficient (dMMR) colon cancer cohort of NEOASIS, an investigator-initiated pan-tumor study sponsored by the Netherlands Cancer Institute (NKI). NEOASIS is evaluating botensilimab (BOT), Agenus' multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus' anti-PD-1 antibody, given …
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Company will release its third quarter 2026 financial results before the market opens on Thursday, November 5, 2026. The earnings release will review Agenus' recent progress in advancing botensilimab and balstilimab (BOT+BAL) toward the Phase 3 neoadjuvant ROBBIN trial in earlier-stage colon cancer and strengthening the clinical and regulatory…
Agenus NASDAQ: AGEN is concentrating its registration strategy for BOT/BAL on the Phase III ROBBIN trial in neoadjuvant high-risk stage II and III microsatellite-stable (MSS) colon cancer, after ending funding for its BATTMAN study in later-line metastatic disease.
Agenus Inc. (NASDAQ: AGEN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Zack Armen, Head of Corporate Development and Investor Relations, will participate in a fireside chat and one-on-one investor meetings at Chardan's 10th Annual Healthcare Conference: The Next 10 Years of Disruptive Innovation, on October 20, 2026. Chardan 10th Annual Healthcare Conference: The Next 10 Years of Disruptive Innovation Date: Tuesday, Oct…
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Armenia--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo® (botensilimab, BOT) and Evamplix® (balstilimab, BAL), each approved for use in combination with the other for the treatment of adult patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases who have previ…
ImageneBio (NASDAQ: IMA - Get Free Report) and Agenus (NASDAQ: AGEN - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations. Insider and Institutional Ownership 75.0% of ImageneBio shares are
Agenus (NASDAQ: AGEN - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at Chardan Capital in a research report issued on Monday, Benzinga reports. They currently have a $40.00 price objective on the biotechnology company's stock. Chardan Capital's target price indicates a potential upside of 378.47% from the stock's previous close.
[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus' multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus' anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemo…
[url="]Agenus Inc.[/url] (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), a
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona. The clinical poster will rev…